Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bencyclane as an anti-sickling agent

R Koçak1, F Başlamişli, B Güvenç

  • 1Department of Medicine and Haematology, Faculty of Medicine, Cukurova University, Adana, Turkey.

British Journal of Haematology
|February 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML.

European review for medical and pharmacological sciences·2021
Same author

Evaluation of the plasma microRNA levels in stage 3 premature retinopathy with plus disease: preliminary study.

Eye (London, England)·2017
Same author

Relationship between MCP1 (-2518A>G) gene variants and ovarian cancer in Turkish population.

Cellular and molecular biology (Noisy-le-Grand, France)·2017
Same author

Glutathione s-transferase m1, t1, and p1 gene polymorphism in exudative age-related macular degeneration: a preliminary report.

European journal of ophthalmology·2017
Same author

Effects of PAX9 and MSX1 gene variants to hypodontia, tooth size and the type of congenitally missing teeth.

Cellular and molecular biology (Noisy-le-Grand, France)·2017
Same author

The Levels of Sera Malondialdehyde, Erythrocyte Membrane Na+-K+/Mg++ and Ca++/Mg++ Adenosine 5' Triphosphatase in Patients with Sickle Cell Anemia.

Turkish journal of haematology : official journal of Turkish Society of Haematology·2016

Bencyclane, an oral medication, shows promise in treating sickle cell anaemia (SCD). It effectively reduced irreversibly sickled cells and improved cellular function in patients, suggesting potential as an anti-sickling agent.

Area of Science:

  • Hematology
  • Pharmacology
  • Cell Biology

Background:

  • Sickle cell anaemia (SCD) is a genetic blood disorder characterized by abnormal hemoglobin leading to red blood cell sickling.
  • Current treatments for SCD focus on managing complications and preventing vaso-occlusive crises.
  • Identifying novel therapeutic agents with anti-sickling properties is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the anti-sickling effect of bencyclane, a vasodilating calcium channel blocker, in patients with homozygous sickle cell anaemia.
  • To assess the impact of bencyclane on erythrocyte ion-transporting ATPase activities and intracellular calcium levels.
  • To determine the efficacy of bencyclane in reducing irreversibly sickled cells (ISCs) and modifying erythrocyte indices.

Main Methods:

Related Experiment Videos

  • A study involving 18 patients with homozygous sickle cell anaemia.
  • Administration of bencyclane as an oral intervention.
  • Measurement of Na(+)-K+ ATPase and Ca(2+)-Mg2+ ATPase activities in erythrocytes.
  • Quantification of intracytoplasmic calcium concentration.
  • Assessment of irreversibly sickled cells (ISCs) and mean corpuscular hemoglobin concentration (MCHC).

Main Results:

  • Bencyclane significantly increased Na(+)-K+ ATPase activity (P < 0.0001) and Ca(2+)-Mg2+ ATPase level (P < 0.0001).
  • Intracytoplasmic calcium concentration was reduced (P < 0.0001) following bencyclane intervention.
  • A significant reduction in irreversibly sickled cells (ISCs) from 21.4% to 14.4% (P < 0.05) was observed.
  • Mean corpuscular hemoglobin concentration (MCHC) of erythrocytes decreased (P < 0.05).

Conclusions:

  • Bencyclane demonstrates a significant anti-sickling effect in patients with sickle cell anaemia.
  • The drug positively modulates erythrocyte ion pump activity and reduces intracellular calcium.
  • Bencyclane is a potential promising oral therapeutic agent for managing sickle cell anaemia.